Cellectar Biosciences
Develops targeted radiotherapeutics for cancer through a phospholipid drug conjugate platform.
Something off on this page? Send us feedback.
Profile
Develops cancer-targeted radiotherapeutics through a phospholipid drug conjugate platform, led by iopofosine for Waldenström macroglobulinemia. It is a pre-revenue, single-segment oncology developer that depends on outside capital and contractors while pursuing regulatory approval.
Develops cancer-targeted radiotherapeutics through its phospholipid drug conjugate platform, which attaches radioactive or other payloads to a phospholipid ether intended to accumulate in cancer cells. Iopofosine is the lead program for relapsed or refractory Waldenström macroglobulinemia; CLR 125 is in early clinical development for refractory triple-negative breast cancer, while CLR 225 and other PDCs remain preclinical.
Operates as a pre-revenue, single-segment oncology developer rather than a product seller. A lean internal team directs research and development alongside contract research organizations, hospitals, academic centers, isotope suppliers, and radiopharmaceutical manufacturers across the United States and internationally.
Future commercialization depends on regulatory approval, financing, and either direct sales capability or partners. Clinical execution and product supply rely on outside vendors for radioactive isotopes, manufacturing, shipping, and compliance.
Company facts
Key statistics
Year to date −27.7% · Average volume (30d) 35.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| May 5, 2026 | Roth Capital | Target | $11 | ||
| Mar 10, 2026 | Maxim Group | Upgrade | Hold | Buy | |
| May 14, 2025 | Maxim Group | Downgrade | Buy | Hold | |
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.52 | −$0.57 | −9.6% | $12.0M | — | — | −4.62% |
| May 14, 2026Q1 FY26 | −$1.89 | −$1.33 | +29.4% | $8.0M | — | — | −3.44% |
| Mar 4, 2026Q4 FY25 | −$1.19 | −$0.53 | +55.5% | $12.8M | — | — | −4.48% |
| Nov 13, 2025Q3 FY25 | −$1.91 | −$1.41 | +26.2% | — | — | — | +1.05% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $110.0K | $0 | |
| Operating income | −$6.4M | −$6.0M | −$4.9M | −$5.7M | −$5.8M | −$7.2M | |
| Net income | −$6.6M | −$5.4M | −$4.4M | −$5.3M | −$5.7M | −$6.9M | |
| Diluted EPS | −$4.30 | −$3.39 | −$1.41 | −$1.25 | −$1.33 | −$0.57 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $34.0M · Total debt $1.5M · Total assets $36.6M · Shareholders' equity $29.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 7.99M · Float 7.50M · 93.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Empery Asset Management, LP | 864.1K | 9.99% | 13G | Aug 4, 2026 |
| Stonepine Capital Management, LLC | 863.3K | 9.90% | 13G | May 11, 2026 |
| SilverArc Capital Management, LLC | 851.3K | 9.99% | 13G | Aug 14, 2026 |
| StemPoint Capital LP | 845.7K | 9.90% | 13G | Aug 14, 2026 |
| Bleichroeder LP | 808.3K | 9.99% | 13G | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | James V. Caruso | director, officer: Chief Executive Officer | +34,720 | $2.88 |
| May 7, 2026 | Jarrod Longcor | officer: Chief Operating Officer | +34,720 | $2.88 |
| Dec 12, 2025 | John Neis | director | −198 | $3.70 |
Peers
- BeOne Medicines (ADR)
Brukinsa is the key WM BTK-inhibitor alternative.
- AbbVie
Imbruvica is an established BTK-inhibitor option in WM.
- Gilead Sciences
Trodelvy provides a mature ADC standard in TNBC.
- Johnson & Johnson
Janssen co-commercializes Imbruvica for WM treatment.
- Merck
Keytruda anchors immunotherapy-based TNBC regimens.
- Novartis (ADR)
Radioligand scale competes for nuclear-medicine capacity.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cellectar Biosciences | $2.60 | +3.39% | $20.2M | — | — | — | — |
| BeOne Medicines (ADR) | $366.73 | −0.01% | $39.19B | 5.1 | 46.7 | 6.9 | +29.6% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Median | 31.1 | 17.0 | 6.3 | +8.4% |